Reviva Pharma up on enrollment updates in late-stage schizophrenia drug trial

Reviva Pharmaceuticals Holdings

22/06/2023 13:59

** Shares of Reviva Pharmaceuticals Holdings Inc  RVPH.O 
rise 9.4% to ~$6 premarket
    ** Drug developer says over 80% of patients have been
enrolled in the pivotal late-stage trial for its lead clinical
candidate, brilaroxazine 
    ** The trial is testing the antipsychotic agent's safety and
efficacy in about 400 patients with acute schizophrenia vs
placebo
    ** Schizophrenia is a chronic, severe mental disorder;
psychotic symptoms include hallucinations and unusual thinking
while negative symptoms include disinterest in daily activities
and social withdrawal
    ** Top-line data from the study expected in Q3'23 
    ** Up to Wednesday's close, stock up 30.4% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))